Y541 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±¤ÁúÄÚƼÄÚÀÌµå ±æÇ×Á¦[¾Ëµµ½ºÅ׷бæÇ×Á¦] | Mineralocorticoid antagonists [aldosterone antagonists] causing adverse effects in therapeutic use |
|
Y542 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ź»ê¾ÈÈ÷µå¶ó¾ïÁ¦Á¦ | Carbonic-anhydrase inhibitors causing adverse effects in therapeutic use |
|
Y542 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¾Æ¼¼Å¸Á¹¾Æ¹Ìµå | Acetazolamide causing adverse effects in therapeutic use |
|
Y543 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â º¥Á¶Æ¼¾Æµð¾ÆÁø À¯µµÃ¼ | Benzothiadiazine derivatives causing adverse effects in therapeutic use |
|
Y544 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â [°í¸®]ÀÌ´¢Á¦ | Loop [High-ceiling] diuretics causing adverse effects in therapeutic use |
|
Y545 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âŸ ÀÌ´¢Á¦ | Other diuretics causing adverse effects in therapeutic use |
|
Y546 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ÀüÇØÁú, Ä®·Î¸® ¹× ¼öºÐÆòÇü Á¦Á¦ | Electrolytic, caloric and water-balance agents causing adverse effects in therapeutic use |
|
Y546 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±¸° Àç¼öÈ¿°·ù | Oral rehydration salts causing adverse effects in therapeutic use |
|
Y547 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¼®È¸È¿¡ ÀÛ¿ëÇÏ´Â Á¦Á¦ | Agents affecting calcification causing adverse effects in therapeutic use |
|
Y547 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ºÎ°©»ó¼± È£¸£¸ó ¹× À¯µµÃ¼ | Parathyroid hormones and derivatives causing adverse effects in therapeutic use |
|
Y547 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ºñŸ¹Î D ±º | Vitamin D group causing adverse effects in therapeutic use |
|
Y548 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¿ä»ê´ë»ç¿¡ ÀÛ¿ëÇÏ´Â Á¦Á¦ | Agents affecting uric acid metabolism causing adverse effects in therapeutic use |
|
Y549 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº ¹«±â¿°·ù | Mineral salts, NEC causing adverse effects in therapeutic use |
|
Y55 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ÀÏÂ÷ÀûÀ¸·Î ÆòÈ°±Ù ¹× °ñ°Ý±Ù°ú È£Èí°èÅë¿¡ ÀÛ¿ëÇÏ´Â Á¦Á¦ | Agents primarily acting on smooth and skeletal muscles and the respiratory system causing adverse effects in therapeutic use |
|
Y550 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ÀڱüöÃ༺ ¾à¹° | Oxytocic drugs causing adverse effects in therapeutic use |
|
Y550 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¸Æ°¢¾ËÄ®·ÎÀ̵å | Ergot alkaloids causing adverse effects in therapeutic use |
|
Y551 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â °ñ°Ý±ÙÀÌ¿ÏÁ¦[½Å°æ±ÙÀ° Â÷´ÜÁ¦] | Skeletal muscle relaxants [neuromusclular blocking agents]causing adverse effects in therapeutic use |
|
Y552 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ÀÏÂ÷ÀûÀ¸·Î ±ÙÀ°¿¡ ÀÛ¿ëÇÏ´Â ±âŸ ¹× »ó¼¼ºÒ¸íÀÇ Á¦Á¦ | Other and unspecified agents primarily acting on muscles causing adverse effects in therapeutic use |
|
Y553 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âħ¾à | Antitussives causing adverse effects in therapeutic use |
|
Y554 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â °¡·¡¾à | Expectorants causing adverse effects in therapeutic use |
|